Medical Center Salutem

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Chronic kidney disease1 trial
• Fatty liver disease (MASLD/MASH)1 trial
• Multiple sclerosis1 trial
• Stroke1 trial

Phase

• Phase 33 trials

Status

• Recruiting2 trials
• Active, not recruiting1 trial

Lead sponsor

• Eli Lilly and Company2 trials
• Hoffmann-La Roche1 trial

Running trials

• Recruiting

  A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

  NCT07241390· Phase 3· Eli Lilly and Company· Source

  Contact: Sergii Lozinskyi (principal investigator)

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

  Contact: Oksana Nyzkoshapka (principal investigator)

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

  NCT04035005· Phase 3· Hoffmann-La Roche· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Chronic kidney disease1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Stroke1 recruiting